Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice

Thrombosis and Haemostasis

Volumn 110, Issue 3, 2013, Pages 582-592

  de Stoppelaar, Sacha F ^a   van 't Veer, Cornelis ^a   van den Boogaard, Florry E ^a   Nieuwland, Rienk ^a   Hoogendijk, Arie J ^a   de Boer, Onno J ^a   Roelofs, Joris J T H ^a   van der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Infectious diseases; Platelet immunology; Protease activated receptors; Streptococcus pneumoniae; Thrombin

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; CONTROLLED STUDY; ENDOTHELIUM CELL; HISTOPATHOLOGY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ANIMALS; BLOOD PLATELETS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; LIVER; LUNG; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDES; PNEUMONIA, PNEUMOCOCCAL; RECEPTORS, THROMBIN; SEPSIS; SPLEEN; STEM CELLS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 84883216761     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-01-0052     Document Type: Article

References (38)

1. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374: 1543-1556.
2. Dockrell DH, Whyte MK, Mitchell TJ. Pneumococcal pneumonia: mechanisms of infection and resolution. Chest 2012; 142: 482-491.
3. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis 2002; 2: 404-415.
4. Levi M, Schultz MJ, Rijneveld AW, et al. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003; 31 (4 Suppl): S238-S242.
5. Shpacovitch V, Feld M, Bunnett NW, et al. Protease-activated receptors: novel PARtners in innate immunity. Trends Immunol 2007; 28: 541-550.
6. Peters T, Henry PJ. Protease-activated receptors and prostaglandins in inflammatory lung disease. Br J Pharmacol 2009; 158: 1017-1033.
7. Sokolova E, Reiser G. A novel therapeutic target in various lung diseases: airway proteases and protease-activated receptors. Pharmacol Ther 2007; 115: 70-83.
8. Ando S, Otani H, Yagi Y, et al. Protease-activated receptor 4-mediated Ca2+ signaling in mouse lung alveolar epithelial cells. Life Sci 2007; 81: 794-802.
9. Ando S, Otani H, Yagi Y, et al. Proteinase-activated receptor 4 stimulation-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res 2007; 8: 31.
10. Vergnolle N, Derian CK, D'Andrea MR, et al. Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J Immunol 2002; 169: 1467-1473.
11. Moffatt JD, Lever R, Page CP. Effects of inhaled thrombin receptor agonists in mice. Br J Pharmacol 2004; 143: 269-275.
12. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-694.
13. Kataoka H, Hamilton JR, McKemy DD, et al. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 2003; 102: 3224-3231.
14. Fujiwara M, Jin E, Ghazizadeh M, et al. Activation of PAR4 induces a distinct actin fiber formation via p38 MAPK in human lung endothelial cells. J Histochem Cytochem 2005; 53: 1121-1129.
15. Soh UJ, Dores MR, Chen B, et al. Signal transduction by protease-activated receptors. Br J Pharmacol 2010; 160: 191-203.
16. Rijneveld AW, Weijer S, Bresser P, et al. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34: 1725-1730.
17. Van Den Boogaard FE, Brands X, Schultz MJ, et al. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 2011; 9: 122-132.
18. Rijneveld AW, Florquin S, Bresser P, et al. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102: 934-939.
19. Hahn I, Klaus A, Janze AK, et al. Cathepsin G and neutrophil elastase play critical and nonredundant roles in lung-protective immunity against Streptococcus pneumoniae in mice. Infect Immun 2011; 79: 4893-4901.
20. Sambrano GR, Weiss EJ, Zheng YW, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-78.
21. Duitman J, Hoogendijk AJ, Groot AP, et al. CCAAT-enhancer binding protein delta (C/EBPdelta) protects against Klebsiella pneumoniae-induced pulmonary infection: potential role for macrophage migration. J Infect Dis 2012; 206: 1826-1835.
22. Lammers AJ, de Porto AP, Florquin S, et al. Enhanced vulnerability for Streptococcus pneumoniae sepsis during asplenia is determined by the bacterial capsule. Immunobiology 2011; 216: 863-870.
23. Dessing MC, Florquin S, Paton JC, et al. Toll-like receptor 2 contributes to antibacterial defence against pneumolysin-deficient pneumococci. Cell Microbiol 2008; 10: 237-246.
24. Paterson GK, Orihuela CJ. Pneumococci: immunology of the innate host response. Respirology 2010; 15: 1057-1063.
25. Schouten M, Wiersinga WJ, Levi M, et al. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83: 536-545.
26. Connolly AJ, Ishihara H, Kahn ML, et al. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-519.
27. Connolly TM, Condra C, Feng DM, et al. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost 1994; 72: 627-633.
28. Asokananthan N, Graham PT, Fink J, et al. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 2002; 168: 3577-3585.
29. Slofstra SH, Bijlsma MF, Groot AP, et al. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood 2007; 110: 3176-3182.
30. Lan RS, Knight DA, Stewart GA, et al. Role of PGE(2) in protease-activated receptor-1,-2 and-4 mediated relaxation in the mouse isolated trachea. Br J Pharmacol 2001; 132: 93-100.
31. Semple JW, Italiano JE, Jr., Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264-274.
32. Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci 2010; 67: 525-544.
33. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70: 6524-6533.
34. Krauel K, Potschke C, Weber C, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparininduced thrombocytopenia. Blood 2011; 117: 1370-1378.
35. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-1389.
36. Su X, Camerer E, Hamilton JR, et al. Protease-activated receptor-2 activation induces acute lung inflammation by neuropeptide-dependent mechanisms. J Immunol 2005; 175: 2598-2605.
37. Borensztajn K, Duitman J, Bruggemann LW, et al. Protease-activated receptor-4 deficiency does not protect against bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 2012; 40: 1056-1057.
38. Schouten M, Van't Veer C, Roelofs JJ, et al. Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study. Crit Care 2012; 16: R238.